LGNDZ

Ligand Pharma Inc Roche Contingent Value Rights

USOTC

Add Alert

LGNDZ

Ligand Pharma Inc Roche Contingent Value Rights

USOTC

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older Newer

surf1944

07/25/12 8:44 AM

Post #138

Re: #137: @surf1944 - LGND PDUFA Fri, July 27, 12am – Sat,

7:17AM Ligand Pharma partner GlaxoSmithKline (GSK) announces priority review from FDA for supplemental new drug application for Promacta for the treatment of thrombocytopenia in adult patients with chronic hepatitis C infection (LGND) 17.64 :

surf1944

06/28/12 8:13 PM

Post #137

Re: #136: @surf1944 - 8:06AM Ligand Pharma Announces 'Positive' preclinical data on

LGND PDUFA Fri, July 27, 12am – Sat, July 28, 12am
Calendar
FDA Calendar

http://www.biorunup.com/categories/FDA_Calendar

surf1944

06/11/12 10:15 AM

Post #136

Re: #135: @surf1944 - 10:19AM Ligand Pharma partner GlaxoSmithKline (GSK) submits U.S.

8:06AM Ligand Pharma Announces 'Positive' preclinical data on LGD-6972 at the American Diabetes Association's 72nd Scientific Sessions (LGND) 13.17 : Co announced today that a poster entitled 'LGD-6972, a Potent, Orally-Bioavailable, Small Molecule Glucagon Receptor Antagonist for the Treatment of Type 2 Diabetes' was presented at the 72nd Scientific Sessions of the American Diabetes Association, June 8-12, 2012, in Philadelphia. The poster provides data from preclinical studies of a novel compound, LGD-6972 that has demonstrated promising glucose lowering activity in various animal models of type 2 diabetes. In preclinical studies, Ligand evaluated the efficacy, pharmacokinetics, and safety of LGD-6972. The key findings include: LGD-6972 is a highly potent and selective glucagon receptor antagonist LGD-6972 inhibits glucagon-induced hyperglycemia in both rats and monkeys LGD-6972 lowers glucose in a mouse model of type 2 diabetes mellitus. The key findings include: LGD-6972 is a highly potent and selective glucagon receptor antagonist LGD-6972 inhibits glucagon-induced hyperglycemia in both rats and monkeys LGD-6972 lowers glucose in a mouse model of type 2 diabetes mellitus Preclinical studies demonstrated robust pharmacokinetics and predict LGD-6972 will be amenable to once daily oral dosing in humans IND-enabling safety studies support the initiation of clinical development planning for LGD-6972.

surf1944

05/30/12 6:15 PM

Post #135

Re: #132: @surf1944 - 8:04AM Ligand Pharma licenses DARA program to Retrophin;

10:19AM Ligand Pharma partner GlaxoSmithKline (GSK) submits U.S. and European regulatory applications for use of Promacta/Revolade to increase platelet counts in patients with hepatitis C (LGND) 12.51 -0.15 : Co's partner GlaxoSmithKline (GSK) announced that it has submitted regulatory applications in the United States and European Union related to eltrombopag (Promacta/Revolade) and its use to increase platelet counts in patients with chronic hepatitis C virus infection and low platelets (thrombocytopenia), specifically: 1) A supplemental New Drug Application to the FDA for Promacta (eltrombopag) as a treatment for thrombocytopenia in adult patients with chronic hepatitis C infection to enable the initiation of interferon-based therapy and to optimize interferon-based therapy. 2) A variation to the Marketing Authorization Application to the European Medicines Agency for Revolade (eltrombopag) as a treatment for thrombocytopenia in adult patients with chronic hepatitis C infection to enable the initiation of interferon-based therapy and during interferon-based therapy.

Penny Roger$ Free

05/01/12 10:30 PM

Post #134

~ Wednesday! $LGND ~ Q1 Earnings posted, pending or coming soon! In Charts and Links Below!

~ $LGND ~ Earnings expected on Wednesday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.

http://stockcharts.com/h-sc/ui?s=LGND&p=D&b=3&g=0&id=p88783918276&a=237480049

http://stockcharts.com/h-sc/ui?s=LGND&p=W&b=3&g=0&id=p54550695994

~ Google Finance: http://www.google.com/finance?q=LGND
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=LGND#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=LGND+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=LGND
Finviz: http://finviz.com/quote.ashx?t=LGND
~ BusyStock: http://busystock.com/i.php?s=LGND&v=2

<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=LGND >>>>>>

http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

Penny Roger$ Free

05/01/12 10:30 PM

Post #133

Re: #127: @ghmm - This is a little dated (September '11) so

surf1944

02/21/12 9:45 AM

Post #132

Re: #130: @surf1944 - Loeb and insiders are also bullish about Xerium

8:04AM Ligand Pharma licenses DARA program to Retrophin; potential for over $75 mln in milestone payments to Ligand plus royalties (LGND) 15.21 : Cos announced that they have entered into an agreement in which Ligand has licensed rights to DARA to Retrophin. Under the terms of the agreement, Ligand will receive a net upfront payment of $1 mln, and may receive, net of amounts owed to third parties, over $75 mln in milestone payments based on clinical and regulatory progress as well as 9% in royalties on potential future worldwide sales by Retrophin. Retrophin intends to develop DARA for orphan indications of severe kidney diseases including Focal Segmental Glomerulosclerosis as well as conduct proof-of-concept studies in resistant hypertension and diabetic nephropathy.

Penny Roger$ Free

02/07/12 6:46 AM

Post #131

~ $LGND ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $LGND ~ Earnings expected on Tuesday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.

http://stockcharts.com/h-sc/ui?s=LGND&p=D&b=3&g=0&id=p88783918276&a=237480049

http://stockcharts.com/h-sc/ui?s=LGND&p=W&b=3&g=0&id=p54550695994

~ Barchart: http://barchart.com/quotes/stocks/LGND?
~ OTC Markets: http://www.otcmarkets.com/stock/LGND/company-info
~ Google Finance: http://www.google.com/finance?q=LGND
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=LGND#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=LGND+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=LGND
Finviz: http://finviz.com/quote.ashx?t=LGND
~ BusyStock: http://busystock.com/i.php?s=LGND&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=LGND&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=LGND
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=LGND
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=LGND
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=LGND
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=LGND
~ MarketWatch: http://www.marketwatch.com/investing/stock/LGND/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=LGND
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=LGND
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=LGND&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=LGND&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=LGND&size=l&frequency=60&color=g

http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

surf1944

01/08/12 8:27 PM

Post #130

Re: #123: @surf1944 - 8:43AM On The Wires (WIRES) : Ligand Pharmaceuticals

Loeb and insiders are also bullish about Xerium Technologies Inc (XRM), Crexus Investment Corp (CXS), Suncoke Energy Inc (SXC), and Ligand Pharmaceuticals Inc (LGND). We like the activist investing style of Loeb a lot. The historical performance of his fund is also outstanding. Additionally, our previous studies have shown that investors can beat the market in the long term simply by imitating the insiders. Therefore, we urge investors to focus on the stock picks of Loeb and insiders, and do some in-depth research about these stocks.

http://seekingalpha.com/article/315718-insiders-and-hedge-fund-star-dan-loeb-are-bullish-about-these-stocks?source=yahoo

mlkrborn

12/21/11 12:31 PM

Post #129

Ligand Pharma announced that it has entered into platform Captisol license and supply agreements with Eli Lilly (LLY) in undisclosed therapeutic areas (LGND) 12.00 : Co announced that it has entered into platform Captisol license and supply agreements with Eli Lilly (LLY) in undisclosed therapeutic areas. During the collaboration, Lilly will be permitted to nominate an unlimited number of drug candidates from its internal pipeline for Captisol formulation. Ligand will provide clinical supplies of Captisol, and may ultimately supply commercial quantities of Captisol to Lilly if a product should be successfully commercialized. Under the terms of the agreement, Ligand will receive a $1 million upfront payment. Other financial terms of the deal were not disclosed.

mlkrborn

12/21/11 12:30 PM

Post #128

ghmm

11/11/11 12:34 PM

Post #127

This is a little dated (September '11) so before the ENABLE-2 top-line info. FYI, The firm follows Ligand and has a $30 target.

http://www.mlvco.com/pdf/MLV%20CALL%20AFDHAL%20SLIDES%209-7-11.pdf

ghmm

11/07/11 1:24 PM

Post #126

There are actually some very interesting abstracts I am just going over them now but a couple compare Promacta and Nplate. While they are small the couple I have seen so far look favorable to Promacta

http://ash.confex.com/ash/2011/webprogram/Paper44106.html

http://ash.confex.com/ash/2011/webprogram/Paper38463.html

mlkrborn

11/07/11 10:47 AM

Post #125

Ligand Pharma announces 'Positive' preclinical data on IRAK4 program at the 2011 American College of Rheumatology Annual scientific meeting (LGND) 15.70 : Co announced that data from preclinical studies on its Interleukin-1 Receptor Associated Kinase-4 program was featured in an oral presentation today at the 2011 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals in Chicago. IRAK4 is a protein kinase involved in immune and inflammatory signaling and has become a high priority novel target for drug development in the areas of oncology and inflammation. IRAK4 inhibitors showed substantially reduced off-target kinase activity. Oral administration of an IRAK4 inhibitor halted disease progression in a mouse model of rheumatoid arthritis.

ghmm

10/19/11 1:12 PM

Post #124

I heard a surprising question on the Roche Q3 call from last week. Someone asked if they expected an impact on Pegasys sales with the promacta data in Hep C. Unfortunately the Roche people on the call couldn't comment (seemed not prepared to answer it).

surf1944

10/19/11 10:22 AM

Post #123

Re: #122: @surf1944 - Ligand Enters Into Global Licensing Agreement With Chiva

8:43AM On The Wires (WIRES) : Ligand Pharmaceuticals (LGND) announced that it has entered into a Captisol license agreement with SAGE Therapeutics for the development and commercialization of Captisol-enabled therapeutics for a broad range of debilitating central nervous system conditions

surf1944

10/12/11 9:18 AM

Post #122

Re: #119: @surf1944 - LIGAND PHARMACEUTICALS (Nasdaq: LGND)

Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn®

Press Release Source: Ligand Pharmaceuticals Incorporated On Monday October 10, 2011, 8:00 am EDT

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - News) announced today that it has entered into a global licensing agreement with Chiva Pharmaceuticals, Inc. for Fablyn (lasofoxifene), a selective estrogen receptor modulator (SERM) that was approved in the EU in 2009 for the treatment of osteoporosis in post-menopausal women at increased risk of fracture. In return for the license, Ligand will receive $4 million in licensing payments over the next eight months and is also eligible to receive milestones and royalties on worldwide sales of Fablyn.

Fablyn was discovered through a research collaboration between Ligand and Pfizer that began in 1991. The drug was fully developed by Pfizer through regulatory approval in the EU. After Pfizer acquired a similar SERM program, Conbriza (bazedoxifene), from its acquisition of Wyeth, Fablyn reverted to Ligand earlier this year.

“The licensing of Fablyn is another transaction demonstrating the strength of the Ligand business model,” said John Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals. “Ligand’s network of worldwide partnerships enables us to quickly move into discussions when a business development opportunity such as Fablyn arises."

"We are delighted to expand our relationship with Chiva," Higgins continued. "Chiva has built an impressive team of management, investors and advisors to drive a company that is largely built around several high-quality Ligand portfolio assets. This agreement enables both Ligand and Chiva to further tap into the burgeoning pharmaceutical investments and enterprise in China. Beyond the obvious benefit of expanding our access to the lucrative Chinese markets and beyond, this transaction further expands our partnered portfolio with another potentially near-term commercial revenue opportunity.”

“The Chiva team is extremely pleased to acquire Fablyn and broaden our partner relationship with Ligand,” said Zhijian (David) Xi, President and Chief Executive Officer of Chiva Pharmaceuticals. “I believe we are raising the bar for new Chinese pharmaceutical companies by acquiring the global rights to a major asset with efficacy and safety data from over 10,000 patients and developed by one of the most reputable companies in the industry. Our ability to acquire an approved asset and potentially launch in the EU in the near future greatly enhances our business model and again differentiates Chiva from many of the emerging pharmaceutical companies in China. I firmly believe that both Ligand and Chiva will continue to benefit from the unique partnership our companies have forged by allowing us to utilize the investment energy and government support in the Chinese pharmaceutical industry to advance assets out of the large Ligand portfolio of proprietary programs.”

About Fablyn

The Ligand and Pfizer collaboration was formed in 1991 to develop therapies for osteoporosis and subsequently produced lasofoxifene (Fablyn), an estrogen partial agonist for osteoporosis treatment and other diseases. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion on December 18, 2008, recommending marketing authorization for Fablyn. The European Commission, which has the authority to approve medicines for the European Union, issued a Marketing Authorization on February 24, 2009.

The International Osteoporosis Foundation (IOF) reports that more than 75 million people suffer from osteoporosis in Europe, Japan and the U.S. About 30% of all post-menopausal women have osteoporosis in Europe and in the U.S., and at least 40% of them will suffer osteoporotic fractures in their lifetime. In Europe alone, 3.78 million osteoporosis-related fractures were reported in 2000, with an estimated cost of 32 billion euros.

ghmm

10/01/11 8:19 AM

Post #121

There was an 8k yesterday late afternoon where BVF has requested to increase their stake up to 19.99%. They were allowed to with the provision the shares above 15% are voted with management nominees. I am quite pleased with this personally!

http://www.sec.gov/Archives/edgar/data/886163/000119312511261444/d237617d8k.htm

acgood

09/14/11 10:10 AM

Post #120

Notes from webcasts and conference calls related to LGND:
http://www.biotechduediligence.com/1/category/ligand/1.html

Detailed notes on LGND's dozens of pipeline programs and partnerships:
http://www.biotechduediligence.com/lgnd.html

surf1944

08/22/11 8:20 AM

Post #119

Re: #118: @surf1944 - Ligand Partner GlaxoSmithKline Receives Positive Data from Promacta®

LIGAND PHARMACEUTICALS (Nasdaq: LGND)
Total Insider buying: $8,930,108.56

There are 13 upcoming Trade Catalysts listed in our calendar including one upcoming Full Phase II trial result for Captisol-Enabled melphalan hydrochloride as indicated for Multiple Myeloma.

Ligands Captisol-enabled melphalan program has been granted Orphan Drug status by the FDA as a conditioning treatment for use in autologous transplant for patients with multiple myeloma. This new IV formulation of melphalan (currently sold as Alkeran for Injection) has the potential to offer multiple advantages for clinicians and patients in the multiple myeloma transplant setting.

Ligand engages in the research, milestone, and royalty revenue activities resulting from its collaborations with pharmaceutical partners. The collaborations primarily include ongoing clinical programs at Bristol-Myers Squibb (BMY), GlaxoSmithKline (GSK), Pfizer (PFE), Merck & Co. (MRK), Cephalon, Inc (CEPH), and Celgene (CELG). These partnered product candidates are being studied for the treatment of indications such as thrombocytopenia, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, osteoporosis, menopausal symptoms, and Alzheimer’s disease.

http://seekingalpha.com/article/288897-10-big-healthcare-stocks-being-snapped-up-by-insiders?source=yahoo

http://www.insidercow.com/history/company.jsp?company=lgnd&B1=Search!

surf1944

07/26/11 7:29 AM

Post #118

Re: #116: @surf1944 - Ligand Enters into Captisol® Commercial Supply Agreement with Merck

Ligand Partner GlaxoSmithKline Receives Positive Data from Promacta® PIII ENABLE1 Study in Hepatitis C-Related Thrombocytopenia

Press Release Source: Ligand Pharmaceuticals Incorporated On Tuesday July 26, 2011, 7:15 am

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - News) today announced that its partner GlaxoSmithKline (NYSE:GSK - News) has announced that it received positive data from ENABLE-1, the first of two Phase III studies examining Promacta (eltrombopag) in patients with hepatitis C-related thrombocytopenia, and that full data will be released at an upcoming scientific conference.

“We are very pleased with GSK’s announcement today about the ENABLE-1 study and we look forward to seeing the full results later this year,” said John Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals. “Promacta is a very important program for Ligand, and the expansion of the franchise into this indication could contribute substantial new revenue to Ligand in the coming years,” added Mr. Higgins.

ghmm

06/24/11 9:06 PM

Post #117

This web page maintained by Biotech Due Diligence has some nice summary information of some of the recent company conference calls and some of their programs.

http://www.biotechduediligence.com/lgnd.html

surf1944

06/24/11 4:06 PM

Post #116

Re: #115: @surf1944 - Ligand Pharma will advance multiple myeloma drug

Ligand Enters into Captisol® Commercial Supply Agreement with Merck
businesswire

Press Release Source: Ligand Pharmaceuticals Incorporated On Monday June 20, 2011, 8:00 am EDT

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - News) announced today that it has entered into a Captisol® supply agreement with Merck & Co., Inc. (NYSE:MRK - News) for an undisclosed program. Ligand will supply clinical and commercial supplies of Captisol and, if the program is approved for commercialization, expects to deliver multiple metric tons of Captisol annually. Financial terms of the deal were not disclosed.

“We are extremely pleased to enter into a long-term commercial supply agreement for this Captisol-enabled program,” said Matt Foehr, Executive Vice President and Chief Operating Officer of Ligand Pharmaceuticals. “This collaboration with Merck is a good example of the type of relationships we try to build with our partners. Merck used Captisol to reformulate a drug in their portfolio and performed initial proof of concept under a research use agreement.”

“This announcement marks the natural transition of the program to a full commercial supply relationship as commercialization approaches,” added Mr. Foehr. “This deal has the potential to add meaningful revenue to the Ligand business in the coming years and extends the already significant partnering relationship that we have developed with Merck over the past few years.”

About Captisol®

Captisol is a patent protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This unique technology was originally developed by Ligand’s subsidiary company CyDex Pharmaceuticals and has enabled five FDA approved products, including Pfizer’s VFEND® IV and Prism Pharmaceuticals’ NEXTERONE®. There are currently over twenty Captisol-enabled® products in development, including Onyx pharmaceuticals’ carfilzomib program.

surf1944

06/24/11 4:06 PM

Post #115

Re: #114: @surf1944 - 8:12AM Ligand Pharma presents Phase IIa data on

Ligand Pharma will advance multiple myeloma drug
Ligand will start new study of multiple myeloma drug, plans to file for approval in mid-2013

On Wednesday June 22, 2011, 2:29 pm EDT

SAN DIEGO (AP) -- Ligand Pharmaceuticals Inc. said Wednesday it will start a new treatment of a potential cancer drug, and if studies are successful, it will seek marketing approval in mid-2013.

Ligand said it plans to start a pivotal trial in early 2012, enrolling about 60 patients with multiple myeloma, a cancer that affects plasma cells in bone marrow. It plans to file with the Food and Drug Administration by mid-2013 if the study is successful. The company is planning to report full results from a mid-stage study during the fourth quarter.

The company is studying a version of the drug melphalan, which is already used to treat multiple myeloma. Ligand said its version of the drug excludes an ingredient that is reported to cause kidney and heart side effects. Those side effects force physicians to use smaller doses of the drug, and Ligand said its version would make it possible to treat patients longer, use slower infusions, and possibly use higher doses safely.

Ligand's drug candidate has received orphan drug status from the FDA, meaning the company will have up to seven years of marketing exclusivity if it is approved. Orphan drug status is given to treatments for rare diseases and to diseases that have few available treatments.

Shares of Ligand Pharmaceuticals rose 19 cents to $10.79 in afternoon trading.

surf1944

06/06/11 10:04 AM

Post #114

Re: #113: @surf1944 - 9:06AM Ligand Pharma and The Medicines Company (MDCO)

8:12AM Ligand Pharma presents Phase IIa data on Captisol-enabled, propylene glycol-free Melphalan at ASCO 2011 (LGND) 10.24 : announced that interim data from a Phase IIa study with its Captisol-enabled, propylene glycol-free, Melphalan program was featured today in a poster presentation at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7, 2011. Co reportd that all patients achieved myeloablation followed by successful engraftment; except for expected grade 2-3 toxicities related to high dose Melphalan, no additional toxicities were reported; PK analysis revealed that the new propylene glycol-free Melphalan met the requirements for establishment of bioequivalence to Alkeran.

surf1944

06/05/11 5:06 PM

Post #113

Re: #111: @surf1944 - Ligand Pharmaceuticals Incorporated (LGND) announces that it has

9:06AM Ligand Pharma and The Medicines Company (MDCO) agree to worldwide license for proprietary Captisol-enabled intravenous formulation of Clopidogrel (LGND) 10.36 : Co and The Medicines Company (MDCO) announced a licensing agreement under which Ligand has licensed exclusive worldwide rights to MDCO for Ligand's Captisol-enabled intravenous formulation of clopidogrel. Ligand will receive an upfront payment of $1.75 million plus be eligible to receive up to $22 million in milestones and up to double digit royalties on annual worldwide net sales. In addition, Ligand will also supply clinical and commercial materials of Captisol for this program, and if the intravenous formulation is approved for commercialization, Ligand will be the exclusive supplier of the product.

ozz collins Free

02/25/11 6:31 PM

Post #112

FDA approval http://ih.advfn.com/p.php?pid=quote&symbol=LGND

surf1944

09/17/10 8:46 AM

Post #111

Re: #110: @surf1944 - Ligand Pharmaceuticals Announces Second Quarter Results

Ligand Pharmaceuticals Incorporated (LGND) announces that it has transferred exclusive license rights to Proximagen Limited for a series of compound hits related to the CXCR4 target with application for a number of indications including those related to the central nervous system. Ligand will receive an upfront payment and continue to be entitled to receive potential future milestone and royalty payments.

surf1944

08/05/10 10:05 AM

Post #110

Re: #109: @surf1944 - Ligand Pharma LGND C.K. Cooper Buy $3.25

Ligand Pharmaceuticals Announces Second Quarter Results

http://finance.yahoo.com/news/Ligand-Pharmaceuticals-bw-572546634.html?x=0&.v=1

surf1944

06/17/10 9:08 AM

Post #109

Ligand Pharma LGND C.K. Cooper Buy $3.25

ghmm

06/15/10 8:50 AM

Post #108

Ligand Board Authorizes Reverse Stock Split and $10 Million Share Repurchase

http://finance.yahoo.com/news/Ligand-Board-Authorizes-bw-387934684.html?x=0&.v=1

The PR may at first seem mixed but I didn't see much revenue (at least from royalties) until after 2011 anyway. Promacta is not yet nor would it be in 2011 at the stage where it is producing meaningful revenue (and the HCV trials won't even have results till mid/late 2011). The Avinza royalty I had totally discounted because a generic is likely very soon and if one notices revenue have already dropped (perhaps the generic already entered late in Q1?) The big surprise is how much they cut their 2011 burn! I really like it they have cut expenses to the bone probably are foregoing any work on all the speculative stuff they have and just let the partnered compounds develop. I like the reverse stock split too as it likely cleans up some of the trader types and may get us more institutional types. I am not counting on a big buyback being executed and their history (with Higgins) is they did follow through on their buyback but one could argue it was a bad investment as the stock continued a downward trend.

Company Forecasts Operational Profitability and Positive Cash Flow from Operations for 2011

Press Release Source: Ligand Pharmaceuticals Incorporated On Tuesday June 15, 2010, 8:00 am

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - News) today announced that its Board of Directors has authorized a reverse stock split of the Company’s common stock and a share repurchase program. Ligand also announced preliminary financial guidance for 2011 and updated financial guidance for 2010.

“Our revenue and financial performance outlook is positive over the foreseeable future,” said John L. Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals. “We have confidence in the business and believe this is an appropriate time to reduce our bloated share count through a reverse stock split as the company moves toward profitability. A higher share price and lower share count also may broaden Ligand's appeal to investors, and reduce per share transaction fees and certain administrative costs. As the Company does not require additional capital to fund operations, we believe it could be a good use of our cash to make selective repurchases of our stock from time to time.”

Mr. Higgins continued, “Currently we are receiving royalties on two commercial products, AVINZA® and PROMACTA®, and we look forward to the market launch of up to four additional royalty bearing products by our partners over the next three years. A total of ten potential products could be launched over the next eight years, coming from our existing portfolio of more than 30 milestone and royalty bearing partnered programs. Importantly, this growth outlook comes as we are substantially lowering spending compared with the past couple of years. We are excited about our business, and look forward to discussing today’s announcement, our product portfolio and business strategies during our Investor and Analyst Meeting later this month.”

Reverse Stock Split

The reverse stock split approved by the Ligand Board of Directors would effect a reverse stock split of the Company’s outstanding common stock at a ratio in the range of 1-for-5 to 1-for-10. The reverse stock split is subject to stockholder approval. The Company will prepare and distribute a proxy statement for a special meeting of stockholders to consider and vote upon a proposal granting Ligand’s Board of Directors the authority to amend the Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock at a ratio in the range mentioned above, with the exact ratio to be determined at the discretion of the Company’s Board of Directors. The timetable, location and other details regarding the special meeting will be communicated to stockholders at a later date. The Company currently expects the reverse stock split to be completed in the third quarter of 2010. As of March 31, 2010, Ligand had 117,579,148 shares of common stock outstanding.

Share Repurchase Program

Ligand’s Board of Directors authorized the Company to repurchase up to $10 million of its common stock from time to time in privately negotiated and open market transactions for a period of up to two years, subject to the Company’s evaluation of market conditions, applicable legal requirements and other factors. The Company is not obligated to acquire common stock under this program, and the program may be suspended at any time.

Financial Guidance

The Company is providing updated guidance for 2010. Ligand now expects total revenue to be approximately $25 million and total operating expenses to be approximately $30 million. Revenue and expenses are both lower than previously forecast due to the anticipated wind-down of certain early, pre-clinical research collaborations in the second half of 2010. Additionally, Ligand currently projects it will have more than $30 million of cash at the end of 2010.

Ligand is also announcing preliminary financial guidance for 2011. The Company expects operating expenses for 2011 to be in the range of $15 million to $18 million, which is approximately one-half of its expected operating expenses for 2010. The significant reduction in projected operating expenses is primarily due to eliminating non-recurring costs for terminated, early stage research collaborations and continued savings from the Company’s restructuring initiated in 2007. Based on current projected royalty and milestone revenues and the reduced expense plan, Ligand expects to be profitable on an operating basis and to have positive cash flow from operations in 2011.

Investor and Analyst Meeting

Ligand’s Investor and Analyst Meeting will take place from 4:15 p.m. Eastern time through 5:45 p.m. Eastern time on Thursday, June 24, 2010 at the Eventi hotel in New York City. A live webcast will be available in the Investor Relations section of www.ligand.com, and also will be available through July 23, 2010. To attend the event in person, please contact Erika Luib at (858) 550-7896.

About Ligand Pharmaceuticals

Ligand discovers and develops new drugs that address critical unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer's, inflammatory diseases, anemia, COPD, asthma, rheumatoid arthritis and osteoporosis. Ligand's proprietary drug discovery and development programs are based on advanced cell-based assays, gene-expression tools, ultra-high throughput screening and one of the world's largest combinatorial chemical libraries. Ligand has strategic alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Merck, Pfizer, Roche, Bristol-Myers Squibb, and Cephalon and more than 30 programs are in various stages of development by its partners.

Forward-Looking Statements

This news release contains certain forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand’s judgment as of the date of this release. Actual events or results may differ from Ligand’s expectations. For example, the reverse stock split may not be completed in accordance with the timing or terms contained in this press release, or at all, and the intended benefits of the reverse stock split, the share repurchase program and expense reductions may not be realized. Likewise, we may not receive expected royalties on AVINZA® from King Pharmaceuticals, PROMACTA® from GSK or any other partnered products or from research and development milestones and we may not be able to timely or successfully advance any product(s) in Ligand’s pipeline. In addition, there can be no assurance that Ligand will achieve its guidance for 2010 or 2011, that Ligand will deliver strong cash flow over the long-term, that Ligand’s 2010 or 2011 revenues will be driven by royalty payments related to AVINZA and PROMACTA sales, that results of any clinical study will be timely, favorable or confirmed by later studies, that products under development by Ligand or its partners will receive regulatory approval in 2010 or later, or that there will be a market for such product(s) if successfully developed and approved. Also, Ligand may experience delays in the commencement, enrollment, completion or analysis of clinical testing for its product candidates, or significant issues regarding the adequacy of its clinical trial designs or the execution of its clinical trials, which could result in increased costs and delays or limit Ligand’s ability to obtain regulatory approval. Further, unexpected adverse side effects or inadequate therapeutic efficacy of Ligand’s product(s) could delay or prevent regulatory approval or commercialization. Ligand may also have indemnification obligations to King Pharmaceuticals or Eisai in connection with the sales of the AVINZA and oncology product lines. In addition, Ligand may not be able to successfully implement its strategic growth plan or continue the development of its proprietary programs. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand’s stock price. Additional information concerning these and other risk factors affecting Ligand’s business can be found in prior press releases available via www.ligand.com as well as in Ligand’s public periodic filings with the Securities and Exchange Commission at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

surf1944

05/05/10 4:16 PM

Post #107

Ligand Pharmaceuticals Announces First Quarter Results
Conference call begins at 4:30 p.m. Eastern time today

Press Release Source: Ligand Pharmaceuticals Incorporated On Wednesday May 5, 2010, 4:05 pm
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - News) today announced financial results for the first quarter of 2010 and provided an operating forecast and program updates.

“Ligand recorded a number of important achievements in the first quarter, beginning with the closing of the Metabasis acquisition in January, and continuing with milestone payments from Merck and more recently Roche under fully funded research partnerships. We continue to make progress with our internal programs as well, including the presentation of positive Phase I data from our SARM program. Looking forward, we believe our diversified product pipeline, productive partnership collaborations and strong spending discipline hold potential to deliver strong cash flow over the long-term,” said John L. Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals.

Financial Results

Total revenues from continuing operations for the three months ended March 31, 2010 were $6.0 million, compared with $9.5 million for the same period in 2009. The decline was primarily due to decreases in collaboration revenues and milestones earned.

Operating costs and expenses from continuing operations in the first quarter of 2010 were $10.4 million, compared with $17.3 million in the first quarter of 2009. Research and development expenses decreased by $3.1 million, primarily due to lower costs associated with clinical trials and lower headcount. General and administrative expenses decreased by $3.8 million, primarily due to reduced legal fees, lower facilities costs and lower headcount.

The net loss in the first quarter of 2010 was $2.8 million, or $0.02 per share, compared with a net loss of $5.1 million, or $0.05 per share, in the comparable 2009 quarter. The loss from continuing operations in the first quarter of 2010 was $3.0 million, or $0.02 per share, compared with a loss from continuing operations of $7.5 million, or $0.07 per share, in the comparable 2009 quarter. Income from discontinued operations in the first quarter of 2010 was $0.2 million, or $0.00 per share, compared with income from discontinued operations of $2.4 million, or $0.02 per share, in the comparable 2009 quarter.

As of March 31, 2010, Ligand had cash, cash equivalents, short-term investments and other current assets of $40.4 million. Cash outflows during the quarter ended March 31, 2010 included approximately $8 million of expected non-recurring payments related to the acquisitions of Neurogen and Metabasis, legal settlement payments and a termination payment related to a collaboration with Bristol-Myers Squibb.

2010 Operating Forecast

Affirming its previous 2010 revenue forecast, Ligand expects 2010 total revenue of approximately $30 million, including approximately $6.0 million of non-cash deferred revenue, consisting of royalty payments from King Pharmaceuticals for sales of AVINZA® and from GlaxoSmithKline (GSK) for sales of PROMACTA, revenue from collaboration agreements and potential milestone payments from existing corporate partners. For the remaining three quarters of 2010, the Company anticipates total operating costs will be approximately $25 million, including non-cash expenses of approximately $4 million.

Select Program Highlights and Outlook

The following is a summary of key programs, including status highlights and outlook for 2010.

Promacta – GlaxoSmithKline

•Revolade has been launched in a number of major markets such as Germany, Sweden and United Kingdom.

SERMs – Pfizer

•Conbriza launch in Europe is expected in the second half of 2010
•Viviant’s pending NDA is expected to receive an FDA advisory committee following a submission of a complete response by Pfizer
•Aprela NDA submission is expected in the second half of 2010

CXCR2 (SCH 527123) – Merck

•A Phase IIb chronic obstructive pulmonary disorder (COPD) trial in 500 patients was initiated in January 2010

CDK (SCH727965) – Merck, Phase II studies ongoing:

•Non-small cell lung cancer (NSCLC)
•Acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL)
•Mantle cell lymphoma (MCL) and B-cell chronic lymphocytic leukemia (B-CLL)

Hepatitis C (RG7348) – Roche

•A $6.5 million milestone payment was earned for progression into Phase I

SARM Program

•First-in-human Phase I single ascending dose data for LGD-4033 was presented at the 14th International Congress of Endocrinology in Kyoto, Japan in March
•Preclinical data on molecular pharmacology on LGD-4033 is scheduled to be presented at the 92nd Annual Meeting of the Endocrine Society in San Diego on June 19, 2010
•Completion and data for Phase Ib multiple ascending dose trial is targeted for the third quarter of 2010

Conference Call

Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss this announcement and answer questions. To participate via telephone, please dial (877) 407-4019 from the U.S. or (201) 689-8337 from outside the U.S., using the passcode “Ligand.” A replay of the call will be available until June 4, 2010 at 5:30 p.m. Eastern time by dialing (877) 660-6853 from the U.S. or (201) 612-7415 from outside the U.S. The account number is 361 and the passcode is 349820. Individual investors can access the Webcast through Ligand’s web site at http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ligandl.com&esheet=6278606&lan=en_US&anchor=www.ligand.com&index=1&md5=ef9afee263e347b6f97264595dfaab50

surf1944

04/20/10 12:12 PM

Post #106

8:00AM Ligand Pharma earns $6.5 million milestone payment from Roche (LGND) 1.75 : The co announces that it earned a $6.5 mln payment from Roche as a result of Roche progressing RG7348 into a Phase I clinical trial for the treatment of hepatitis C viral (HCV) infection. The milestone payment arises from a 2008 collaboration and license agreement between Roche and Metabasis Therapeutics, Inc. Ligand acquired Metabasis in January 2010. Ligand's net proceeds from the milestone payment will be approximately $2.3 million after paying $4.2 million to others including holders of the Ligand-issued "Roche" CVR.

loridans

04/19/10 9:52 PM

Post #105

Re: #103: @surf1944 - 8:00AM Ligand Pharma presents first-in-human Phase I Data

Annotated chart from another board

hptaxis

03/29/10 10:05 AM

Post #104

Re: #103: @surf1944 - 8:00AM Ligand Pharma presents first-in-human Phase I Data

It will be interesting to see what happens with this program. Recently, GTx terminated their SARM relationship with Merck I foresee a great number of problems with SARM R&D.

surf1944

03/29/10 9:35 AM

Post #103

8:00AM Ligand Pharma presents first-in-human Phase I Data on lead SARM Molecule LGD-4033 at the International Congress of Endocrinology (LGND) 1.78 : Co announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured. This Phase I clinical trial was the first study in humans of LGD-4033, and evaluated the safety, tolerability and pharmacokinetic profiles of the molecule in a single escalating dose, double blind, placebo-controlled study in 48 healthy volunteers. The key findings include: LGD-4033 was well tolerated by healthy male volunteers after single oral doses up to 22 mg, the highest dose tested. No serious adverse events (SAE) or clinically significant dose-related adverse events were reported. Systemic exposure of LGD-4033 increased proportionally with the dose level after a single oral dose. Sustained systemic exposure was observed with appreciable plasma levels of LGD-4033 detectable a week post-dose. LGD-4033's half-life was consistent with a regimen of once-daily oral dosing.

mlkrborn

03/13/10 3:34 AM

Post #102

Ligand, Glaxo drug gets European approval
Ligand Pharmaceuticals, GlaxoSmithKline blood disorder drug receives European approval
ap

On Friday March 12, 2010, 1:32 pm EST

SAN DIEGO (AP) -- Ligand Pharmaceuticals Inc. said Friday that partner GlaxoSmithKline gained European regulatory approval to sell the blood disorder drug Revolade.

In December, a European advisory committee recommended approving the drug. It was discovered by Ligand, is already approved in the U.S. as Promacta. Ligand's licensing partner GlaxoSmithKline handled the European application.

Thrombocytopenia purpura is rare blood condition that involves low platelet counts, making it more difficult for blood to clot.

Shares of Ligand rose 3 cents to $1.71 in afternoon trading. GlaxoSmithKline shares fell 14 cents to $37.73.

surf1944

02/09/10 8:38 AM

Post #101

Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Results
Conference Call and Webcast Begins 9:00 a.m. Eastern Time Today

Press Release Source: Ligand Pharmaceuticals Incorporated On Tuesday February 9, 2010, 8:00 am
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - News) today announced financial results for the three and 12 months ended December 31, 2009, and reviewed business highlights of the fourth quarter of 2009 and early 2010.

“2009 was an exceptional year for Ligand with many scientific, business and financial accomplishments. The year culminated with positive Phase Ia trial data for our SARM program, our partners receiving European approvals for Fablyn® and Conbriza™ (Viviant), milestone payments from fully-funded collaborations with GlaxoSmithKline, Merck and Pfizer and the acquisitions of Neurogen and Metabasis,” said John L. Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals.

“Ligand has assembled an unparalleled partnership portfolio of 33 externally-funded programs with the potential to earn significant revenues. We are simultaneously advancing our internal pipeline toward additional news events and possible out-licensing opportunities in 2010,” added Higgins.

Fourth Quarter Results

Total revenues from continuing operations for the three months ended December 31, 2009 were $14.0 million, compared with $12.4 million for the same period in 2008. The increase is primarily due to $9.2 million in collaboration revenues resulting from agreements acquired in connection with Ligand’s acquisition of Pharmacopeia, Inc. in December 2008, partially offset by a $4.0 million decrease in milestone revenues and a $3.6 million decrease in royalty revenues due to the change in the contractual royalty rate on AVINZA® that became effective in the fourth quarter of 2008.

Operating costs and expenses from continuing operations in the fourth quarter of 2009 were $13.1 million, compared with $86.3 million in the fourth quarter of 2008, which included a $72.0 million write-off of acquired in-process research and development in connection with the acquisition of Pharmacopeia. Excluding the write-off of acquired in-process research and development, operating costs and expenses were $14.3 million in the fourth quarter of 2008. Research and development expenses decreased by $1.0 million for the fourth quarter of 2009, compared with the same period in 2008, primarily due to lower costs associated with clinical trials. General and administrative expenses decreased by $0.2 million, compared with the same period in 2008, primarily due to lower headcount-related costs.

Income from continuing operations in the fourth quarter of 2009 was $1.0 million, or $0.01 per share, compared with a loss from continuing operations of $73.7 million, or $0.76 per share, in the fourth quarter of 2008. Income from discontinued operations in the fourth quarter of 2009 was $2.0 million, or $0.02 per share, compared with $4.1 million, or $0.04 per share, in the fourth quarter of 2008.

Net income in the fourth quarter of 2009 was $3.0 million, or $0.03 per share, compared with a net loss of $69.6 million, or $0.72 per share, for the same period in 2008. Excluding $72.0 million of write-off of acquired in-process research and development, net income in the fourth quarter of 2008 was $2.4 million, or $0.02 per share.

As of December 31, 2009, Ligand had cash, cash equivalents, short-term investments and restricted investments of $54.7 million.

Full-Year Results

Total revenues for the year ended December 31, 2009 were $38.9 million, compared with $27.3 million in 2008. Operating costs and expenses for the year ended December 31, 2009, including $15.2 million of lease termination costs, were $70.8 million, compared with operating costs and expenses of $126.6 million, including $72.0 million of write-off of acquired in-process research and development, in 2008. Excluding lease termination and write-off charges, expenses were $55.1 million in 2009 compared with $54.6 million in 2008. The slight increase in annual expenses was primarily due to additional costs incurred to service our collaboration agreements offset by lower expenses associated with our internal programs and reduced legal expenses. The net loss for the year ended December 31, 2009 was $1.9 million, or $0.02 per share, compared with a net loss of $98.1 million, or $1.03 per share in 2008.

Select Program Highlights and Outlook

The following is a summary of key programs with status highlights and outlook for 2010.

Promacta – GlaxoSmithKline

Recommended for European approval for ITP in December 2009, projected European launch in 2010
NDA filed in Japan for ITP in September 2009
Two Phase III hepatitis C trials recently completed full enrollment
Ligand currently earning royalties from U.S. product sales

CXCR2 (SCH 527123) – Merck

Phase IIa trials for COPD and asthma completed
Two 500-patient Phase IIb trials recently initiated for COPD and asthma
Ligand eligible to earn milestone payments and royalties

p38 (BMS-582949) – Bristol Myers Squibb

Phase II Proof of Concept trial for rheumatoid arthritis completed
Phase II trial for atherosclerosis is ongoing
Ligand eligible to earn milestone payments and royalties

Acadesine Program – PeriCor/Merck

Ongoing 7,500 patient Phase III trial for Coronary Artery Bypass Graft (CABG)
Trial projected to be completed second half 2010
Ligand eligible for royalties

Beta-Secretase – Merck

Phase I single dose administration showed a 58% reduction in A-Beta Peptide in the cerebral/spinal fluid; Phase I rising dose trial ongoing for Alzheimer’s disease
Phase II trial projected to begin in 2010
Ligand eligible to earn milestone payments and royalties

JAK-3 Program for Inflammatory Disease – Pfizer

Pfizer extended research collaboration with Ligand by one year
To date, Ligand has earned over $15 million in research payments
Ligand eligible to earn milestone payments and royalties

GlaxoSmithKline Collaboration

Eight compounds nominated to date with two compounds nominated in 2009
Potential for achieving milestones in 2010 for advancing a lead drug candidate
Ligand eligible to earn milestone payments and royalties

Organon/Schering-Plough Research Collaboration

$4 million in milestones recently paid for certain undisclosed research programs
Research phase of the collaboration ended December 2009
Ligand eligible to earn additional milestone payments and royalties

SARM Program

Successful completion of Phase Ia trial in 2009
Initiation of Phase I multi-dose trial for SARM in February 2010
Completion and data for Phase Ib trial targeted for third quarter of 2010
Objective to seek partnership following Phase I trial completion

Metabasis and Neurogen acquisitions closed giving Ligand:

Collaborations with Roche (hepatitis C) and Merck (pain)
Research programs for diabetes, hyperlipidemia and Alzheimer’s disease
Cash and other assets

2010 Financial Outlook

For 2010, Ligand currently estimates total revenues of approximately $30 million, generally comprised of royalties, milestone payments, research payments and $6 million of non-cash deferred revenue. This revenue outlook does not include revenue from new licensing deals for the company’s lead research programs. Ligand currently projects operating expenses of approximately $35 million, including $2 million of accretion of deferred gain on sale leaseback and $7 million of non-cash depreciation and stock-based compensation expense.

Webcast and Conference Call

Ligand’s President and Chief Executive Officer, John L. Higgins, will present fourth quarter financial results and provide a business update at the BIO CEO & Investor Conference today at 9:00 a.m. Eastern time (6:00 a.m. Pacific time). The conference takes place at the Waldorf-Astoria Hotel in New York City. A live webcast of the presentation will be available on Ligand’s website www.ligand.com. To access the presentation via telephone please dial (877) 407-4019, passcode: Ligand.

A replay of the presentation will be archived for 30 days on www.ligand.com and via telephone at (877) 660-6853, Account: 361# passcode: 343412.

About Ligand Pharmaceuticals

Ligand discovers and develops new drugs that address critical unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, frailty, , inflammatory diseases, anemia, asthma, rheumatoid arthritis and osteoporosis. Ligand's proprietary drug discovery and development programs are based on advanced cell-based assays, gene-expression tools, ultra-high throughput screening and one of the world's largest combinatorial chemical libraries. Ligand has strategic alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Merck, Pfizer, Roche, Celgene, and Cephalon and more than 30 molecules are in various stages of development by its partners.

Forward-Looking Statements

This news release contains certain forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. Actual events or results may differ from Ligand's expectations. For example, we may not receive expected royalties on AVINZA from King Pharmaceuticals, PROMACTA from GSK or any other partnered products or from research and development milestones, and we may not be able to timely or successfully advance any product(s) in Ligand's pipeline. In addition, there can be no assurance that Ligand will achieve its guidance for 2010, that Ligand will deliver strong cash flow over the long term, that Ligand will realize the expected benefits of the acquisitions of Neurogen and Metabasis, that Ligand's 2010 revenues will be driven by royalty payments related to AVINZA and PROMACTA sales, that Ligand will be able to create future revenues and cash flows by developing innovative therapeutics, that results of any clinical study will be timely, favorable or confirmed by later studies, that products under development by Ligand or its partners will receive regulatory approval, or that there will be a market for the product(s) if successfully developed and approved. Also, Ligand may experience delays in the commencement, enrollment, completion or analysis of clinical testing for its product candidates, or significant issues regarding the adequacy of its clinical trial designs or the execution of its clinical trials, which could result in increased costs and delays, or limit Ligand's ability to obtain regulatory approval. Further, unexpected adverse side effects or inadequate therapeutic efficacy of Ligand's product(s) could delay or prevent regulatory approval or commercialization. Ligand may also have indemnification obligations to King Pharmaceuticals or Eisai in connection with the sales of the AVINZA and oncology product lines and may be subject to future tax liabilities which are larger than the provision for income taxes reflected in Ligand’s 2009 year-end financial statements. In addition, Ligand may not be able to successfully implement its strategic growth plan and continue the development of its proprietary programs. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand's stock price. Additional information concerning these and other risk factors affecting Ligand's business can be found in prior press releases available via www.ligand.com as well as in Ligand's public periodic filings with the Securities and Exchange Commission at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

LIGAND PHARMACEUTICALS INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

Three Months Ended
December 31,
Twelve Months Ended
December 31,

2009 2008 2009 2008
Revenues:
Royalties $ 1,811 $ 5,389 $ 8,334 $ 20,315
Collaborative research and development and other revenues 12,163 7,000 30,606 7,000
Total revenues 13,974 12,389 38,940 27,315
Operating costs and expenses:
Research and development 10,127 11,063 39,870 30,770
General and administrative 3,021 3,206 15,211 23,785
Lease termination costs — — 15,235 —
Write-off of acquired in-process research and development — 72,000 442 72,000
Total operating costs and expenses 13,148 86,269 70,758 126,555
Accretion of deferred gain on sale leaseback (425 ) (491 ) (21,851 ) (1,964 )
Gain (loss) from operations 1,251 (73,389 ) (9,967 ) (97,276 )
Other income (loss) (220 ) (575 ) 95 (239 )
Gain (loss) before income taxes 1,031 (73,964 ) (9,872 ) (97,515 )
Income tax (expense) benefit — 234 — 55
Income (loss) from continuing operations 1,031 (73,730 ) (9,872 ) (97,460 )
Discontinued operations:
Gain on sale of AVINZA Product Line before income taxes 95 2,297 5,434 9,584
Gain (loss) on sale of Oncology Product Line before income taxes 372 1,939 955 (10,630 )
Income tax benefit (expense) on discontinued operations 1,535 (133 ) 1,535 392
Discontinued operations 2,002 4,103 7,924 (654 )
Net income (loss) $ 3,033 $ (69,627 ) $ (1,948 ) $ (98,114 )

Basic and diluted per share amounts:
Loss from continuing operations $ 0.01 $ (0.76 ) $ (0.09 ) $ (1.02 )
Discontinued operations 0.02 0.04 0.07 (0.01 )
Net income (loss) $ 0.03 $ (0.72 ) $ (0.02 ) $ (1.03 )
Weighted average number of common shares - basic 113,382 96,841 113,177 95,505
Weighted average number of common shares - diluted 113,510 96,841 113,177 95,505

LIGAND PHARMACEUTICALS INCORPORATED

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

December 31,
2009
December 31,
2008

Assets
Current assets:
Cash, cash equivalents and short-term investments $ 53,232 $ 80,671
Other current assets 5,152 2,300
Current portion of co-promote termination payments receivable 9,782 10,958
Total current assets 68,166 93,929

Restricted investments 1,462 1,341
Property and equipment, net 8,522 12,903
Goodwill and other identifiable intangible assets 2,515 5,375
Long-term portion of co-promote termination payments receivable 30,993 47,524
Restricted cash - indemnity account — 10,232
Other assets 2,041 144
Total assets $ 113,699 $ 171,448

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued liabilities $ 35,577 $ 35,972
Allowance for loss on returns, rebates and chargebacks 31 9,590
Current portion of deferred gain 1,702 1,964
Current portion of deferred revenue 4,989 10,301
Current portion of co-promote termination liability 9,782 10,958
Current portion of equipment financing obligations 91 1,829
Total current liabilities 52,172 70,614

Long-term portion of co-promote termination liability 30,993 47,524
Long-term portion of deferred gain 1,702 23,292
Long-term portion of deferred revenue 3,495 16,819
Other long-term liabilities 13,249 11,219
Total liabilities 101,611 169,468

Common stock subject to conditional redemption 8,344 12,345
Stockholders' equity 3,744 (10,365 )
Total liabilities and stockholders' equity $ 113,699 $ 171,448

Contact:
Ligand Pharmaceuticals IncorporatedJohn L. Higgins, President and CEOErika Luib, Investor Relations(858) 550-7896orLippert/Heilshorn & Associates, Inc.Don Markley(310) 691-7100dmarkley@lhai.com

surf1944

01/07/10 3:29 PM

Post #100

Ligand Earns $1 Million in Milestone Payment from Merck & Co., Inc.

Press Release Source: Ligand Pharmaceuticals Incorporated On Thursday January 7, 2010, 3:00 pm
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - News) announced today that it has received a $1 million milestone payment from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that expired on December 31, 2009. The payment is a result of achieving a discovery milestone. In total, Ligand has earned $4 million from this collaboration over the past few months.

Schering-Plough (Merck) Research Collaborations

Pharmacopeia and Organon entered into the collaboration and license agreement in February 2007 to discover, develop and commercialize therapeutic products across a broad range of indications. Ligand assumed responsibility for the collaboration as a result of its acquisition of Pharmacopeia in December 2008.

mlkrborn

12/23/09 1:46 PM

Post #99

Ligand Announces Positive Regulatory Opinion in Europe for Revolade for Chronic Immune Thrombocytopenic Purpura

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner GlaxoSmithKline (NYSE: GSK) has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP)

The CHMP has recommended the marketing authorization of eltrombopag in the European Union for the treatment of ITP in adult patients who have had their spleen removed, and who do not respond to other treatments, such as corticosteroids and immunoglobulins therapies. Eltrombopag may also be considered as a second-line treatment for adult patients where surgery to remove their spleen is contraindicated

“Approval in Europe presents an expanded market opportunity for eltrombopag and is an exciting development for Ligand as it continues to validate Ligand’s success in contributing to the discovery of novel and important commercial therapies,” said John L. Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals. “Eltrombopag enjoys in excess of 10 years remaining patent life in both the U.S. and Europe, and the European approval of Revolade expands the commercial potential for the drug. We commend GSK for their clinical and regulatory successes and commitment to developing eltrombopag for other indications.” ITP patients experience bruising and bleeding and, in some cases, serious hemorrhages, which can be fatal. ITP may also affect a patient’s quality of life, as it is often associated with fatigue and depression1 and a fear of bleeding may limit everyday activities.2 Traditional treatments with corticosteroids, immunoglobulins or splenectomy (removal of the spleen) all have potential drawbacks for chronic treatment of ITP patients.5, 6, 7 Eltrombopag significantly increases platelet counts The positive opinion from CHMP is based on two Phase III randomized, double-blind, placebo-controlled clinical trials (TRA100773B8 and RAISE TRA1025379) and two open-label studies (REPEAT TRA10805710 and EXTEND TRA10532511) in adults who have previously received treatment for chronic ITP. The studies showed that the patients treated with eltrombopag (plus the standard of care) experienced significant increases in platelet counts, a reduction in the incidence of bleeding and an improvement in quality of life, compared with those receiving placebo (plus the standard of care) 8,9,11. Eltrombopag treatment has also allowed patients to reduce the dose of their concomitant medications, such as steroids.9 In clinical trials, eltrombopag was well-tolerated.8,12 In some cases, nausea and vomiting were recorded in the eltrombopag group and not in the placebo group.8 Elevation of liver enzymes was also seen, but these were mostly mild, reversible and not accompanied by any clinically significant symptoms that would indicate impaired liver function.8 Eltrombopag is the first oral platelet generator Eltrombopag is an oral, non-peptide, thrombopoietin receptor agonist. It stimulates the proliferation and differentiation of megakaryoctes, resulting in an increase in platelet counts. Megakaryocytes are the bone marrow cells that give rise to blood platelets.13 About eltrombopag Eltrombopag was given accelerated approval by the U.S. Food and Drug Administration (FDA) under the trade name Promacta® in November 2008, for the treatment of chronic ITP in adults who have had an insufficient response to corticosteroids, immunoglobulins or surgical removal of the spleen. Eltrombopag is also approved under the trade name Revolade® in Venezuela, Kuwait, Chile and Russia. In addition, orphan designation was granted by the European Commission for eltrombopag for the treatment of ITP on August 3, 2007.14 Eltrombopag was discovered as a result of a research collaboration between GSK and Ligand Pharmaceuticals, and developed by GSK

About chronic ITP Chronic ITP is a serious condition, where patients have low platelet levels in the blood. Platelets are essential to normal clotting, so patients with ITP are at increased risk of bleeding, and may develop bruises and experience nose or gum bleeds, have blood in the urine or feces, abnormally heavy menstrual bleeding, or other types of bleeding that is difficult to stop.14 Although very rare in occurrence, bleeding in the brain is potentially fatal.15 Quality of life is adversely affected in patients with chronic ITP, with a fear of bleeding limiting patients’ daily activities.2 Fatigue and depression are, also, often associated with the disease.1 Revolade® and Promacta® are registered trade marks of the GlaxoSmithKline group of companies. Information based on GSK’s press release

About Ligand Pharmaceuticals Ligand discovers and develops new drugs that address critical unmet medical needs of patients with muscle wasting, frailty, hormone-related diseases, osteoporosis, inflammatory diseases, anemia, asthma, rheumatoid arthritis and psoriasis. Ligand's proprietary drug discovery and development programs are based on advanced cell-based assays, gene-expression tools, ultra-high throughput screening and one of the world's largest combinatorial chemical libraries. Ligand has strategic alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Merck and Pfizer. With more than 20 molecules in various stages of development, Ligand utilizes proprietary technologies for identifying drugs with novel receptor and enzyme drug targets

References 1

Platelet Disorder Support Association (PDSA): About ITP. http://www.pdsa.org/itp-information/index.html Accessed November 2009

2

Mathias SD, Gao SK, Miller KL, et al. Impact of chronic immune thrombocytopenic purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes 2008; 6:13

3

National Heart, Lung, and Blood Institute: Diseases and Conditions Index. http://www.nhlbi.nih.gov/health/dci/Diseases/Itp/ITP_WhatIs.html. Accessed May 2009

4

Cines DB, McMillan R. Management of Adult Idiopathic Thrombocytopenic Purpura. Annu Rev Med, 2004;56:425-52 5

Stasi R, Provan D. Management of Immune Thrombocytopenic Purpura in Adults. Mayo Clin Proc. 2004;79:504-522 6

McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004;104: 956-960 7

Bussel JB, Eldor A, Kelton JG, et al. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost. 2004; 91:771–8 8

Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641-8

9

Cheng G, Saleh M, Bussel J, et al. Oral eltrombopag for the long-term treatment of patients with chronic idiopathic thrombocytopenic purpura: results of a Phase III, double-blind, placebo-controlled study (RAISE). Blood 2008;112:400. [ASH Annual Meeting Abstracts]

10

Psaila B, Bussel J, Vasey S, et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic ITP. Abstract 0294 presented at the 13th congress of the European Haematology Association, June 2008

11

Saleh M, Bussel JB, Cheng G, et al. Eltrombopag is efficacious in patients with refractory chronic idiopathic thrombocytopenic purpura (ITP) – data from the EXTEND Study. Blood 2008; 112:401 [ASH Annual Meeting Abstracts]

12

Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-47

13

Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 2009; 27:424-30

14

EMEA. Committee for Orphan Medicinal Products. Public summary of positive opinion for orphan designation of eltrombopag olamine for the treatment of idiopathic thrombocytopenic purpura, 2009:1-4

15

National Heart, Lung, and Blood Institute: Diseases and Conditions Index. http://www.nhlbi.nih.gov/health/dci/Diseases/Itp/ITP_WhatIs.html. Accessed November 2009

Caution Regarding Forward-Looking Statements This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand’s judgment as of the date of this release. These forward-looking statements include comments regarding eltrombopag and other drug candidates, data analysis and evaluation of eltrombopag, utility or potential benefits to patients, the potential commercial market for eltrombopag and plans for continued development and further studies of eltrombopag. Actual events or results may differ from Ligand’s expectations. For example, there can be no assurance that other trials or evaluations of eltrombopag or other product candidates will be favorable or that they will confirm results of previous studies, that data evaluation will be completed or demonstrate any hypothesis or endpoint, that eltrombopag or other product candidates will provide utility or benefits to certain patients, that any presentations will be favorably received, that eltrombopag or other product candidates will be useful, that marketing applications will be filed or, if filed, approved, or that clinical or commercial development of these product candidates will be initiated, completed or successful or that our rights to eltrombopag and other related product candidates will not be successfully challenged. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand’s stock price. Additional information concerning these and other risk factors affecting Ligand can be found in prior press releases available at www.ligand.com as well as in public periodic filings with the Securities and Exchange Commission, available at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this press release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995

Bookmark With :
Facebook MySpace Twitter Digg Del.icio.us StumbleUpon Reddit Google Bookmarks Newsvine Technorati Furl AIM Slashdot Yahoo

Ligand Pharmaceuticals Incorporated Historical Chart Ligand Pharmaceuticals Incorporated Intraday Chart
Period
noad

hptaxis

11/20/09 8:46 AM

Post #98

Re: #97: @surf1944 - Ligand Presents New Preclinical Data on its Lead

SARMs: Big Hype - Long Pathway To Approval

If you recall, GTXI has a similar compound, Ostarine. The SARMs from all available have the same side effects of AAS, particularly induced hypogonadism.

The pathway to approval will not be easy. Like AAS, they will find their way, if not already, to the nonprescription user. While this does not mean nonapproval, it does mean increased scrutiny by regulators.

surf1944

11/20/09 8:06 AM

Post #97

Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting

Press Release
Source: Ligand Pharmaceuticals Incorporated
On 8:00 am EST, Friday November 20, 2009

Companies:Ligand Pharmaceuticals Inc.
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - News) today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis.

The key findings include:

LGD-4033 increased bone mineral density and bending strength (an indicator of resistance to fracture) in osteopenic female rats, a model of post-menopausal osteoporosis, by increasing the rate of new bone formation and reducing bone turnover. Statistically significant improvements in bone mineral density were observed after 12 weeks of administering LGD-4033 at doses as low as 0.03 mg/kg/day in cortical bone and 0.3 mg/kg/day in cancellous bone.
LGD-4033 potently increased the skeletal muscle mass and the average diameter of the individual muscle fibers in both hypogonadal and hormonally-normal rats. Muscle fiber diameter is known to correlate with the maximum contractile force that can be generated by a muscle fiber, suggesting greater muscle strength following LGD-4033 administration.
Unlike the potent full agonist activity observed with the increase in skeletal muscle and bone, LGD-4033 treatment resulted in a significant reduction in prostate mass at all doses tested (up to 100 mg/kg/day). Steroidal androgens are known to cause prostate hyperplasia. The reduction in prostate mass, together with an increase in muscle and bone formation, represents a unique and desirable tissue-selective profile of LGD-4033.

According to Martin D. Meglasson, Ph.D., Ligand’s Vice President of Discovery Research, “SARMs are promising drugs to treat the serious problem of muscle wasting that occurs in patients with a variety of disorders, including cancer cachexia and sarcopenia in the elderly. The findings reported today demonstrate that LGD-4033 has the potential to be an important new option for these patients by offering improved safety compared to currently available drugs based on its tissue selective effect. As muscle wasting and osteoporosis are common co-morbidities in the elderly, LGD-4033 may be particularly beneficial to frail, elderly patients by improving their mobility and quality-of-life, and reducing the risk of fall-related bone fractures.”

vladster

11/05/09 10:37 PM

Post #96

Re: #94: @surf1944 - Ligand's JAK3 Research Collaboration Extended by Pfizer

Hey surf what was your take on the CC this afternoon?

mlkrborn

11/05/09 12:58 PM

Post #95

$1.70s..

surf1944

11/05/09 8:34 AM

Post #94

Ligand's JAK3 Research Collaboration Extended by Pfizer

Press Release
Source: Ligand Pharmaceuticals Incorporated
On 8:30 am EST, Thursday November 5, 2009

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - News) announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization. Under the original agreement, Ligand is entitled to receive up to $175 million in milestone payments for the successful development and commercialization of multiple products. In addition, Ligand will receive royalties on product sales.

“We are very pleased to learn that Pfizer has elected to extend the JAK3 research collaboration with Ligand,” said John L. Higgins, President and Chief Executive Officer of Ligand. “We view JAK3 inhibitors as a very promising market opportunity, and given Pfizer's clinical success with its own internal program we are convinced that they are highly committed to this category. Ligand has an exceptional record of drug discovery while serving major pharmaceutical companies in a number of research collaborations. We are pleased with the team’s progress and look forward to continued success as we drive the program forward for Pfizer.”

About JAK3

JAK3 is a tyrosine kinase that belongs to the Janus family of enzymes, and it is an important target for therapeutic interventions in the treatment of autoimmune disorders, inflammation, and organ transplant rejections. JAK3 expression seems to be limited to hematopoietic cells, and specific inhibitors of JAK3 could represent a new class of immunosuppressant drugs.

vladster

11/04/09 11:37 AM

Post #93

Re: #92: @surf1944 - 8:30AM Ligand Pharma amended its license agreement with

Earnings today. Surfs up or down?

surf1944

11/02/09 9:12 AM

Post #92

8:30AM Ligand Pharma amended its license agreement with Exelixis (LGND) 1.70 : Co has amended its license agreement with Exelixis, Inc. (EXEL) as a result of which Ligand is now entitled to receive royalties on net sales of future products from a mineralocorticoid receptor program and a one-time $75,000 payment for providing access to certain patent rights. Also, as a result of Ligand's settlement with Salk last year, the amendment eliminated certain minimum annual royalties that may have been payable by Exelixis.

surf1944

10/30/09 10:52 AM

Post #91

Re: #90: @vladster - What's wrong with this stock?

The whole small cap biotech sector including LGND has been falling for the past couple of months, even on good news most can not hold their bids. You may see weakness for the next few weeks until tax loss selling is completed. I follow a couple hundred of these stocks & they are all very weak.

surf

vladster

10/30/09 10:46 AM

Post #90

Re: #89: @mlkrborn - Ligand buying MBRX?

What's wrong with this stock?

Bleeding down now steady since above $3 in August. Seems like they struck a couple of nice little deals on Neurogen and Metabasis which should have added value to the company yet we see a 40% decline in market cap!

mlkrborn

10/27/09 10:01 AM

Post #89

Ligand buying MBRX?

Older Newer

Ligand Pharma Inc Roche Contingent Value Rights (LGNDZ)

Followers	24	Posters	40
Posts (Today)	0	Posts (Total)	188
Created	03/21/07	Type	Free
Moderators

http://www.ligand.com/

http://finance.yahoo.com/q/h?s=LGND

Ligand Pharmaceuticals Incorporated, a biotech company, engages in the discovery and development of drugs in the United States. It has research and development collaborations with pharmaceutical companies, including GlaxoSmithKline; Wyeth; Pfizer, Inc.; and TAP Pharmaceutical Products, Inc. for the treatment of market indications, such as thrombocytopenia, osteoporosis, menopausal symptoms, and frailty. The company?s partnered products include Eltrombopag, a small-molecule TPO mimetic for thrombocytopenia, which is in phase III clinical trials; bazedoxifene, a monotherapy for osteoporosis; Aprela, a combination of bazedoxifene with PREMARIN for osteoporosis prevention, and vasomotor symptoms of menopause; and lasofoxifene, for osteoporosis and vaginal atrophy, which is in phase III clinical trials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.